Sage Therapeutics (SAGE) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (10.04 million) in Sage Therapeutics (SAGE). On Tuesday, The value of composite uptick trades was $140.24 million, whereas, the value of composite downtick trades was $150.28 million and the ratio between the two was 0.93, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $8.63 million. $1.6 million was the block trade value on upticks. The ratio between the two was clearly in favor of the bears at 0.19. The negative money flow of ($7.02 million) shows selling on strength. Sage Therapeutics (SAGE) gained $12.56 intraday at $46.21 and registrered 37.33% for the week.
The company Insiders own 18.6% of Sage Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.92% . Institutional Investors own 90.12% of Sage Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -17.66%. In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director 10% owner of Sage Therapeutics, Inc., Starr Kevin P had sold 850,000 shares worth of $26,562,500 in a transaction dated May 16, 2016. In this transaction, 850,000 shares were sold at $31.25 per share.
Shares of Sage Therapeutics, Inc. rose by 47.73% in the last five trading days and 52.06% for the last 4 weeks. Sage Therapeutics, Inc. is up 32.6% in the last 3-month period. Year-to-Date the stock performance stands at -20.74%.
Sage Therapeutics (NASDAQ:SAGE): stock turned positive on Tuesday. Though the stock opened at $48.67, the bulls momentum made the stock top out at $49.89 level for the day. The stock recorded a low of $44.62 and closed the trading day at $46.21, in the green by 37.33%. The total traded volume for the day was 12,469,467. The stock had closed at $33.65 in the previous days trading.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.